Patients do not usually think about who sits in a corner office when they queue for a repeat prescription. They think about whether the medicine is in stock, whether the pharmacist can help, whether the price is fair, and whether they can get out before the day disappears. Ivan Saltzman stepping back from Dis-Chem’s executive role matters beyond boardroom gossip for these reasons.
After 48 years in the business, the 75-year-old co-founder has retired from executive duty, closing a chapter that began with a single pharmacy in Mondeor, Johannesburg, in 1978. Dis-Chem grew from that one store into a multi-billion-rand, JSE-listed retailer that changed how many people buy medicines, vitamins, baby products, and everyday health items.
A founder who changed pharmacy retail
Saltzman and his wife, Lynette, started Dis-Chem with a clear idea: medicine should be cheaper and easier to buy. That simple proposition ended up reshaping a whole sector. Dis-Chem built large stores, packed them with product lines, and turned the pharmacy into a destination rather than a quick stop.
That model forced everyone else to respond. Independent pharmacies had to defend their place on service. Big chains had to sharpen their pricing and broaden what they offered. Consumers got used to comparing pharmacies the way they compare supermarkets, by range, convenience, and value.
By 2024, Dis-Chem had grown to more than 300 pharmacies and 60 retail stores, including Baby City and The Local Choice, across South Africa, Botswana, and Namibia. This scale makes Saltzman’s exit more than a personal retirement. It marks the end of the founder era at a retailer that helped redraw the map.
What stays the same
Saltzman is not walking out the door completely. He will remain a non-executive director, which means he still has a seat at the table, but not the day-to-day job of running the business. This distinction matters. A founder can shape culture for decades, yet the operating tempo eventually belongs to the executive team.
The current chief executive, Rui Morais, took over on 1 July 2023 after 13 years as group chief financial officer. Tony Healy, who had been group retail executive, became CFO. That succession plan suggests Dis-Chem has already been moving into its next phase, with a heavier focus on efficiency, systems, and margins than on founder instinct alone.
The public version of that strategy is straightforward: keep the value promise, keep the customer base, and improve the mechanics behind the scenes. For shoppers, that usually translates into the same question in a different form: will the shelf price, service level, and stock availability still hold up?
What may change for shoppers
Dis-Chem’s next phase is likely to look less like a reinvention and more like a tightening. Expect more attention on supply chain efficiency, private label products, and the way online and in-store shopping connect. This is the practical language behind a modern pharmacy strategy.
For consumers, the possible effects sit in a few areas.
- Prices could stay aggressive if Dis-Chem keeps pushing internal efficiency.
- Private label ranges may expand, giving shoppers cheaper alternatives to branded products.
- Clinic services may become more prominent, especially for vaccinations, screenings, and basic consultations.
- Refill and booking systems may become more digital, reducing friction for repeat users.
- Click-and-collect and delivery could matter more as customers want pharmacy shopping to feel less like a chore.
None of that sounds dramatic until you remember how many people use pharmacies for everyday care, not just emergencies. A better refill process or a more useful clinic can save a family time and transport costs. A poor one sends them back to the doctor or into another queue.
Why the sector will feel it
Clicks is the obvious rival to watch. Dis-Chem and Clicks have spent years defining the South African pharmacy retail market between them, but they do not play exactly the same game. Dis-Chem has leaned into large-format stores with wider product ranges. Clicks has often been the more compact convenience option, especially in high-traffic shopping centres.
Saltzman’s departure will not suddenly change that rivalry, but it may sharpen it. A more data-driven Dis-Chem under Morais could force Clicks to keep investing in pricing, clinics, loyalty, and digital tools. That competition can help patients if it pushes both chains to improve access and service.
Independent pharmacies sit under more pressure. They cannot match the scale of a national chain, and they usually do not have the same buying power or loyalty machinery. Their edge is personal care and local trust. The problem is that trust alone does not always beat a lower price on chronic medicine or a broader product range on the same trip.
What to watch next
The real test is whether Dis-Chem protects the thing that made it different while making the business more efficient. Large retailers often lose their edge when they chase neat management logic and forget why people came in the first place.
For patients, the useful questions are practical:
- Is your usual medicine still easy to find there?
- Are clinic wait times improving or getting worse?
- Do the loyalty and private label offers still save you money?
- Is the pharmacy becoming easier to use for repeat scripts and bookings?
Saltzman built a company that taught South African shoppers to expect more from a pharmacy. His retirement does not erase that legacy. It does, however, put pressure on the next leadership team to prove that the model can survive without the man who started it.
